B16-bl6 Cells
B16-bl6 Cells - Related Videos
07:31
Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
0 Views •
Cited by 13 •
2016
Metastasis plays a profound role in the virulence of cancer, accounting for an estimated 90% of deaths. We report a protocol for a metastatic melanoma model in mice that is useful for determining the efficacy of therapeutic agents against this clinical phenomenon.
03:52
Experimental Metastatic Melanoma Mouse Model: A Platform to Study the Metastatic Potential of Melanoma Cells in the Lungs
0 Views •
2023
In this video, melanoma cells are intravenously injected through the tail vein in the mouse model. The melanoma cells further travel through the circulatory system, adapting to the distant microenvironment and causing metastasis in organs like lungs.
09:09
An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets
0 Views •
Cited by 8 •
2016
Distinct dendritic cell subsets exist as rare populations in lymphoid organs, and therefore are challenging to isolate in sufficient numbers and purity for immunological experiments. Here we describe a high efficiency, high yield method for isolation of all of the currently known major subsets of mouse splenic dendritic cells.
09:23
Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation
0 Views •
Cited by 4 •
2016
Cancer cells are embedded in a collagen gel and then sandwiched in an acellular fibrin gel to generate a 3D culture system in which the invasiveness and formation of satellite tumors may be monitored.
02:43
Tumor Implantation and Injection of a Tumor Vaccine in a Mouse Model
0 Views •
2025
This video demonstrates a cell-based tumor vaccination assay. A mouse, intradermally injected with B16-F10 melanoma cells for tumor formation, is vaccinated with B16-F10 cells secreting Flt3L cytokine near the developed tumor. The secreted Flt3L from the vaccine promotes the maturation and proliferation of dendritic cells that then present tumor antigens to T cells in lymph nodes, triggering a targeted anti-tumor immune response.
FAQs
Their aggressive growth and metastatic behavior create a model in which investigators can examine how tumor cells progress and spread. These characteristics are especially useful when research focuses on invasion or the development of anti-metastatic strategies. The cells therefore support analysis of cancer biology at both the cellular level and the level of tumor progression.
Studying these cells in syngeneic C57BL/6 mice preserves an intact immune system during tumor experiments. This setting lets investigators examine interactions between malignant cells and host immune responses as tumors develop. It is therefore useful for preclinical questions involving immunotherapy or immune-related effects on tumor behavior.
The model supports focused study of tumor progression, immune responses, angiogenesis, and invasion. These represent distinct dimensions of cancer behavior that can be examined in relation to one another. Assessing them within the same experimental system can help clarify which biological process a treatment or experimental condition influences.
Using both settings allows investigators to connect controlled cellular experiments with tumor behavior in animals. In vitro studies provide a controlled context for examining cell-related mechanisms, whereas in vivo studies place those findings within tumor progression and immune interactions. Together, these approaches help determine whether cellular observations correspond to therapeutic outcomes in a preclinical model.
Investigators can use the model to evaluate potential therapies, including immunotherapy and anti-metastatic agents, while examining effects on tumor progression and related biology. Its value lies in linking a treatment intervention to measurable changes in an aggressive tumor model. This supports assessment of therapeutic concepts within controlled cellular and animal experiments.
Researchers can examine whether an intervention affects tumor progression, immune responses, angiogenesis, or invasion. Immunotherapy is particularly relevant to the immune dimension, whereas anti-metastatic agents relate to metastatic behavior. Comparing these outcomes helps show whether a treatment influences broad tumor biology or appears directed toward a particular process.